Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
Top Cited Papers
- 27 August 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 167 (3), 668-677
- https://doi.org/10.1111/j.1365-2133.2012.11168.x
Abstract
Background Tofacitinib is a novel, oral Janus kinase inhibitor under investigation as a potential treatment for plaque psoriasis. Objectives This Phase 2b, 12‐week, dose‐ranging study (A3921047, NCT00678210) aimed to characterize the exposure–response, efficacy and safety of tofacitinib vs. placebo in patients with moderate‐to‐severe chronic plaque psoriasis. Methods One hundred and ninety‐seven patients were randomized. The primary endpoint was the proportion of patients achieving a ≥ 75% reduction in the Psoriasis Area and Severity Index (PASI 75) score at week 12. Results At week 12, PASI 75 response rates were significantly higher for all tofacitinib twice‐daily groups: 25·0% (2 mg; P < 0·001), 40·8% (5 mg; P < 0·0001) and 66·7% (15 mg; P < 0·0001), compared with placebo (2·0%). Significant increases in the proportion of PASI 75 responses were seen by week 4 and were maintained at week 12. Exposure–response over the 0–15 mg tofacitinib twice‐daily dose range was successfully characterized. PASI 50, PASI 90 and Physician’s Global Assessment response rates were also higher for tofacitinib vs. placebo. The most frequently reported adverse events (AEs) were infections and infestations: 22·4% (2 mg twice daily), 20·4% (5 mg twice daily), 36·7% (15 mg twice daily) and 32·0% (placebo). Discontinuations due to AEs were 6·0%, 2·0%, 4·1% and 6·1% of patients in the placebo, and 2, 5 and 15 mg twice‐daily tofacitinib groups, respectively. Dose‐dependent increases from baseline in mean serum high‐density lipoprotein, low‐density lipoprotein and total cholesterol, and decreases in haemoglobin and neutrophils were observed. Conclusion Short‐term treatment with oral tofacitinib results in significant clinical improvement in patients with moderate‐to‐severe plaque psoriasis and is generally well tolerated.Keywords
This publication has 19 references indexed in Scilit:
- Consensus Guidelines for the Management of Plaque PsoriasisArchives of Dermatology, 2012
- New Insights in the Immunologic Basis of PsoriasisSeminars in Cutaneous Medicine and Surgery, 2010
- Evaluation and Management of Psoriasis: An Internist's GuideMedical Clinics of North America, 2009
- JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J MicePublished by The American Association of Immunologists ,2009
- Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III studyThe Lancet, 2008
- Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case?control studyBritish Journal of Dermatology, 2007
- Risk of Myocardial Infarction in Patients With PsoriasisJAMA, 2006
- Psoriasis Phenotype at Disease Onset: Clinical Characterization of 400 Adult CasesJournal of Investigative Dermatology, 2005
- The prevalence of psoriasis in African Americans: Results from a population-based studyJournal of the American Academy of Dermatology, 2005
- Age at onset and different types of psoriasisBritish Journal of Dermatology, 1995